BioSpace News Archive

INVICTUS MD STRATEGIES CORP. is pleased to announce that further to its news release dated May 16, 2018, it has successfully entered into a definitive option agreement with a Late-Stage Applicant (“OptionCo”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to acquire 100% (the “Option”) of the outstanding shares of OptionCo from its current shareholders

James R. Vasselli MD to Lead Clinical Development

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

Showed the potential of CSTI-300 as an efficacious and well tolerated drug candidate for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).

Leading experts in primary care will gather to discuss strategies to improve the patient-provider relationship

Summit in Boston, MA, October 17-19, 2018 at the Renaissance Waterfront Boston Hotel.

Fresenius Kabi now offers 0.2 mg per mL, 0.4 mg per 2 mL, 1 mg per 5 mL, and 4 mg per 20 mL presentations

WWE and O.A.R. have teamed up to raise awareness and funds for Connor’s Cure through O.A.R.’s Just Like Paradise tour this summer.

ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies—ClaimIt. ClaimIt removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and accelerating data capture – all of which help reduce exorbitant costs for study sponsors and create opportunities to leverage the data capture from connected devices for clinical evaluation.

The U.S. Food and Drug Administration (FDA) today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.